Friedemann Übele

Friede is a biotech engineer with a decade of experience in development and manufacturing of pharmaceutical products. He has a bachelors degree in biotechnology from the Esslingen University of Applied Sciences, Germany and a masters degree in process engineering from the University of Stuttgart, Germany. Within Novartis, he was involved in the build-up and operational launch of the first commercial Cell & Gene manufacturing facility for Novartis in Europe. His focus was on a paper free cleanroom and compliance to aseptic requirements. In 2021, Friede moved on to Tigen Pharma, a Swiss biotech company in the field of cell therapies to cure cancer. Tigen is a disruptive catalyst, combining a unique culture with a multidisciplinary set of clinical and technical capabilities and a long-term perspective to the benefit of patients and society.